Detection of serum anti v-raf murine sarcoma viral oncogene homologue B1 antibodies in patients with rheumatoid arthritis and the assessment of its clinical significance
10.3760/cma.j.issn.1007-7480.2014.04.006
- VernacularTitle:类风湿关节炎患者血清抗鼠科肉瘤病毒癌基因同源物B1抗体检测及临床意义探讨
- Author:
Yang LI
;
Hong ZHU
- Publication Type:Journal Article
- Keywords:
Arthritis,rheumatoid;
Anti v-raf murine sarcoma viral oncogene homologue B1 anti-bodies;
Biomedical research
- From:
Chinese Journal of Rheumatology
2014;18(4):240-243
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the serum levels of anti-BRAF antibody in patients with rheumatoid arthritis (RA) and its clinical significance.Methods Blood samples from 129 patients with RA,71 patients with other rheumatic diseases and 68 healthy controls were measured by enzyme-linked immunosorbent assays (ELISA).The serum levels of anti-BRAF antibody in patients with RA were divided into high,medium and low groups,each group had 43 cases.The clinical symptoms,immunological findings and related imaging data of all cases were recorded.We investigated the relationship between the serum levels of anti-BRAF antibody and the clinical symptoms,immunological findings and related imaging changes of the RA group.Chi-square test,Mann-Whitney U test,Spearman's correlation test were used for statistical analysis.Results ① The serum levels of anti-BRAF antibody were significantly higher in RA group [A:1.093 (0.150-3.210)] than in other rheumatic diseases group [A:0.278 (0.093-0.455)] and healthy controls [A:0.202 (0.121-0.443)] (Z=-11.223,P=0.021 ; Z=-7.839,P=0.008 7).The serum levels of anti-BRAF antibody was not significantly different between patients with other rheumatic diseases group and healthy controls (Z=-0.905,P=0.445).② The difference in positive rate of rheumatoid factor (RF) in different groups of anti-BRAF antibody levels was statistically significant (λx2=10.14,P=0.006),namely the positive rate was significantlyhigher in the low-level group (88％) than in the high-level group (58％) (x2=10.03,P=0.002).Thepositive rate of anti-cyclic citrullinated peptide antibody and anti-keratin antibody of the three groups was not significantly different (x2=0.721,P=0.697; x2=1.735,P=0.188).③ There was significant negative correlation between the levels of anti-BRAF antibody and the course of disease (r=-0.233,P=0.047),RF(r=-2.84,P=0.039),IgM (r=-0.234,P=0.038),and hemoglobin (r=-0.287,P=0.032).There was no significant correlation between the level of anti-BRAF antibody and the joint swelling index (r=-0.133,P=0.230),joint pain index (r=-0.173,P=0.100),other clinical and laboratory parameters.There was significantly negative correlation between the ESR and hemoglobin level.④ There was no significant difference of the level of anti-BRAF antibody between the normal group and patients with bone destruction in the RA group (Z=-0.642,P=0.521).⑤ There was no significant difference in the level of anti-BRAF antibody between the normal group and patients with interstitial pulmonary fibrosis group in the RA group (Z=-0.121,P=0.904).Conclusion The anti-BRAF antibody can be used for the diagnosis of RA as a new autoantibody,and it can also be used in the diagnosis of early or RF-negative RA.There is no correlation between the level of anti-BRAF antibody and bone destruction and interstitial pulmonary fibrosis.
